Skip to main content
Log in

Changes in neurotransmitters in multiple sclerosis

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Abstract

Patients with multiple sclerosis were found to have increased cerebrospinal fluid, noradrenaline, and excitatory amino acid (glutamate and aspartate) levels, with increased blood glutamine, asparagine, and glycine levels. An association was found between these biochemical parameters and the nature and severity of neurological symptoms, as well as with the course of the disease. Neurotransmitters are proposed to have a role in the pathogenesis of multiple sclerosis, particularly in the biochemical mechanisms of the relationship between the nervous and immune systems, as well as in the neurochemical mechanisms underlying the development of neurological deficit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. É. G. Larskii, V. P. Barkhatova, and E. G. Demin. Lab. Delo,9, 519–522 (1985).

    PubMed  Google Scholar 

  2. D. L. Bellinger, D. Lorton, and S. Y. Felten, Int. J. Immunopharmacol.,14, No. 3, 329–344 (1992).

    Article  PubMed  CAS  Google Scholar 

  3. E. Chelmicka-Schorr and B. G. Arnason, Ann. Neurol.,36, Suppl., 29–32 (1994).

    Article  Google Scholar 

  4. A. Compston, Ann. Neurol.,36, Suppl., 146–150 (1994).

    Article  Google Scholar 

  5. R. A. Davidoff, in: The Origin and Treatment of Spasticity, R. Benecke, M. Emre, and R. Davidoff (eds.), USA (1990), pp. 63–91.

  6. C. D. Dijkstra, E. R. van der Voort, C. J. de Groot, et al., Psychoneuroendocrinology,19, No. 2, 135–142 (1994).

    Article  PubMed  CAS  Google Scholar 

  7. V. Gallai, P. Sarchielli, C. Firenze, et al., Acta Neurologica Belgica,94, No. 1, 44–52 (1994).

    PubMed  CAS  Google Scholar 

  8. J. Jackson, R. Cross, and R. Walker, Immunology,54, 505–512 (1985).

    PubMed  CAS  Google Scholar 

  9. J. W. Karaszewski, A. T. Reder, D. Anlar, et al., Ann. Neurol.,30, 42–47 (1991).

    Article  PubMed  CAS  Google Scholar 

  10. J. W. Karaszewski, A. T. Reder, D. Anlar, and G. W. Arnason, J. Neuroimmunol.,43, No. 1-2, 1–7 (1993).

    Article  PubMed  CAS  Google Scholar 

  11. F. Lechin, D. van der Dijs, A. Lechin, et al., J. Med.,25, No. 3-4, 181–192 (1994).

    PubMed  CAS  Google Scholar 

  12. S. Lipton and R. Rosenberg, New England J. Med.,330, 613–622 (1994).

    Article  CAS  Google Scholar 

  13. W. H. Oertel, in: Spasticity: The Current Status of Research and Treatment, M. Emre and R. Benecke (eds.), USA (1989), pp. 27–44.

  14. J. W. Prineas and F. Connell, Curr. Neurol.,28, 68–75 (1979).

    Google Scholar 

  15. J. S. Wolinsky, Curr. Neurol.,13, 167–207 (1993).

    Google Scholar 

Download references

Authors

Additional information

Institute of Neurology, Russian Academy of Medical Sciences, Moscow. Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 97, No. 5, pp. 7–10, May, 1997.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barkhatova, V.P., Zavalishin, I.A., Askarova, L.S. et al. Changes in neurotransmitters in multiple sclerosis. Neurosci Behav Physiol 28, 341–344 (1998). https://doi.org/10.1007/BF02464784

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02464784

Keywords

Navigation